Clinical Application of Screening Cell Combination Method in the Prediction of Red Blood Cell Alloantibody.
10.19746/j.cnki.issn.1009-2137.2021.04.049
- Author:
Xiao-Fei LI
1
;
Rong LANG
2
;
Xue-Qin DIAO
3
;
Rui-Rui SU
2
;
Yuan ZHANG
2
;
Bin HU
2
Author Information
1. Department of Blood Transfusion, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China ,E-mail:lixiaofei@ccmu.edu.cn.
2. Department of Blood Transfusion, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
3. Jinan Blood Supply and Protection Center, Jinan 250001, Shandong Province, China.
- Publication Type:Journal Article
- MeSH:
Autoantibodies;
Blood Group Antigens;
China;
Erythrocytes;
Humans;
Isoantibodies
- From:
Journal of Experimental Hematology
2021;29(4):1325-1329
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the clinical application of screening cell combination method in the prediction of red blood cell alloantibody, so as to provide basis for clinical diagnosis.
METHODS:From October 2018 to April 2020, 9 680 samples were screened with automatic blood group instrument, 79 patients with positive alloantibodies were identified by 4 sets of screening cells from different manufacturers (referred to as combined method). At the same time, cell panel Panocell-16 was used for comparative analysis. Meanwhile, the combined method was also used to identify the antibodies of 20 samples from National Center for Clinical Laboratories external quality assessment (EQA) in China and 12 samples from WHO EQA.
RESULTS:The 79 alloantibodies included anti-Mia antibody (7 cases), anti-M antibody (13 cases), anti-Le
CONCLUSION:The combined method can identify the alloantibodies of red blood cells in Chinese population. The screening cells can be used for screening of irregular antibodies without wasting reagents at the same time.
